The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection.
第一作者:
Peilong,Lai
第一单位:
Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.;State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, PR China.;Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 510530, Guangzhou, PR China.
作者:
医学主题词
动物(Animals);疾病模型, 动物(Disease Models, Animal);女(雌)性(Female);乙型肝炎(Hepatitis B);乙型肝炎病毒(Hepatitis B virus);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);男(雄)性(Male);小鼠(Mice);中年人(Middle Aged);前体细胞淋巴母细胞白血病淋巴瘤(Precursor Cell Lymphoblastic Leukemia-Lymphoma);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);T淋巴细胞(T-Lymphocytes);治疗结果(Treatment Outcome);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1038/s41375-020-0952-4
PMID
32632097
发布时间
2021-02-09
- 浏览6
Leukemia
2790-2793页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



